AEON at a glance
The past year
Chart−85.7% $0.12, close Nov 18
- From the highest close
- −90.9%
- Vs the 200-day average
- −79.7%
Short interest
History2.7M shares
- Of shares outstanding
- 3.16%
- Since the last report
- −18.1%
- Days to cover
- 6.4 days
- Settled
- Oct 30, 2026
Insider buying, 7 days
FilingsNone filed this week
- Form 4s filed
- Nov 13 – Nov 19
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
AEON price history
Loading recent earnings…
Investment thesis
What must happen next
ABP-450 creates value only if regulators and clinicians accept a credible Botox-biosimilar path toward broad U.S. labeling; a requirement for materially larger, slower, or narrower development would break the core asset thesis.HoldingMateriality: High
The company description identifies AEON as advancing proprietary botulinum toxin complex ABP-450 as a biosimilar to Botox with the goal of full-label U.S. approval. If the pathway holds, AEON owns a potentially partnerable therapeutic toxin asset; if it fails, the business has no visible commercial engine.
Watch: The FDA requires a full standalone clinical program rather than accepting a Botox-biosimilar comparability pathway.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
The company description identifies AEON as advancing proprietary botulinum toxin complex ABP-450 as a biosimilar to Botox with the goal.
Open source ↗Capital access is a gating operating capability: AEON must raise financing or partner ABP-450 quickly enough to fund development, or the asset option decays regardless of scientific promise.WeakeningMateriality: High
GAAP cash and cash equivalents were $3.006 million at FY2025 year-end. For common owners, even a good asset can become worthless if development pauses, restructures, or is financed on punitive terms.
Watch: Microcap biotech equity markets close to AEON or demand deeply dilutive issuance before a value-creating ABP-450 milestone.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP cash and cash equivalents were $3.006 million at FY2025 year-end.
Open source ↗AEON must reduce or refinance its liability overhang without transferring most of ABP-450’s economics away from common shareholders; otherwise clinical progress may accrue mainly to creditors or new money.WeakeningMateriality: Medium
GAAP liabilities were $60.587 million at FY2025 year-end. The claim separates asset value from per-share value: ABP-450 can improve while existing holders are still diluted or subordinated.
Watch: Existing creditors convert, amend, or enforce claims on terms that absorb most future ABP-450 upside.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP liabilities were $60.587 million at FY2025 year-end.
Open source ↗Management must keep spending focused on value-inflecting ABP-450 milestones rather than broad, unfunded development activity; otherwise burn will destroy the option before the next regulatory or partnering event.HoldingMateriality: Medium
GAAP annual operating cash flow improved from negative $35.584 million in FY2022 to negative $17.308 million in FY2025. Cost discipline extends runway and improves negotiating leverage; undisciplined spending forces distressed financing.
Watch: AEON restarts multiple clinical programs or indications before securing dedicated financing.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating cash flow improved from negative $35.584 million in FY2022 to negative $17.308 million in FY2025.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
ABP-450 creates value only if regulators and clinicians accept a credible Botox-biosimilar path toward broad U.S. labeling; a requirement for materially larger, slower, or narrower development would break the core asset thesis. If the pathway holds, AEON owns a potentially partnerable therapeutic toxin asset; if it fails, the business has no visible commercial engine.
Capital access is a gating operating capability: AEON must raise financing or partner ABP-450 quickly enough to fund development, or the asset option decays regardless of scientific promise. For common owners, even a good asset can become worthless if development pauses, restructures, or is financed on punitive terms.
AEON must reduce or refinance its liability overhang without transferring most of ABP-450’s economics away from common shareholders; otherwise clinical progress may accrue mainly to creditors or new money. The claim separates asset value from per-share value: ABP-450 can improve while existing holders are still diluted or subordinated.
Management must keep spending focused on value-inflecting ABP-450 milestones rather than broad, unfunded development activity; otherwise burn will destroy the option before the next regulatory or partnering event. Cost discipline extends runway and improves negotiating leverage; undisciplined spending forces distressed financing.
All standing thesis claims
Original report summary
AEON is a highly leveraged, cash-constrained call option on ABP-450 becoming a credible U.S. Botox biosimilar, not a proven operating business yet.
Bull case and bear case
Bull case and bear case for AEON Biopharma
Where the evidence on AEON Biopharma disagrees: Mixed on the latest evidence (Nov 17, 2026). Of its 4 thesis points, 2 holding and 2 weakening.
Bull case: what the evidence supports
ABP-450 creates value only if regulators and clinicians accept a credible Botox-biosimilar path toward broad U.S. labeling; a requirement for materially larger, slower, or narrower development would break the core asset thesis.
Management must keep spending focused on value-inflecting ABP-450 milestones rather than broad, unfunded development activity; otherwise burn will destroy the option before the next regulatory or partnering event.
Bear case: what the evidence questions
Capital access is a gating operating capability: AEON must raise financing or partner ABP-450 quickly enough to fund development, or the asset option decays regardless of scientific promise.
AEON must reduce or refinance its liability overhang without transferring most of ABP-450’s economics away from common shareholders; otherwise clinical progress may accrue mainly to creditors or new money.
Thesis-Break Engine
Thesis-break watch · AEON Biopharma
OptimistFi is watching AEON Biopharma. No break-condition checks are on record yet — they accumulate as new filings are checked.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
No assessed change was returned in this research window. That can reflect a quiet period or a coverage limit.
Risks / falsifiers
What could break the thesis
- The FDA requires a full standalone clinical program rather than accepting a Botox-biosimilar comparability pathway.
- Microcap biotech equity markets close to AEON or demand deeply dilutive issuance before a value-creating ABP-450 milestone.
- Existing creditors convert, amend, or enforce claims on terms that absorb most future ABP-450 upside.
- AEON restarts multiple clinical programs or indications before securing dedicated financing.
AEON news
Loading headlines…
Financial statements
AEON income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
AEON: quick answers
- When does AEON Biopharma (AEON) report earnings next?
- AEON Biopharma's next results are projected for February 15, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 16, 2026. Earnings calendar
- What is AEON's short interest?
- As of October 30, 2026, 2.7M AEON shares were sold short, 3.16% of its shares outstanding, down 18.1% from the count before. At the stock's average daily volume that is 6.4 days to cover. FINRA publishes the count twice a month. AEON short interest history

